Skip to main content

Advertisement

Table 2 Changes in detrended fluctuation analysis (DFA) values, Parkinson’s disease sleep scale (PDSS) and unified Parkinson’s disease rating scale (UPDRS)

From: Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson’s disease

Variable Mean changes from baseline (95%CI) Between group difference (96%CI)
YXQN Placebo YXQN vs Placebo P value
α value of DA     
  Week 8 −0.9 [−1.1 to −0.7] −0.2 [−0.3 to 0.1] −0.7 [−1.0 to −0.8] 0.056
  Week 12 −1.0 [−1.2 to −0.7] −0.1 [−0.3 to 0.2] −0.8 [−1.1 to −0.7] 0.051
  Week 16 −0.9 [−1.1 to −0.6] −0.2 [−0.2 to 0.3] −0.9 [−1.1 to −0.7] 0.072
α value of EA     
  Week 8 −1.1 [−1.4 to −0.6] −0.1 [−0.1 to 0.2] −1.0 [−1.3 to −0.5] 0.048
  Week 12 −0.9 [−1.0 to −0.6]* 0.1 [−0.3 to 0.4] −1.1 [−1.6 to −0.7] 0.036
  Week 16 −0.9 [−1.1 to −0.7]* −0.2 [−0.4 to 0.3] −0.9 [−1.3 to −0.8] 0.041
α value of NA     
  Week 8 1.0 [0.8 to 1.6]* −0.3 [−0.6 to 0.4] 1.1 [0.7 to 1.5] 0.017
  Week 12 1.1 [0.7 to 1.5]* −0.1 [−0.5 to 0.5] 1.0 [0.6 to 1.4] 0.038
  Week 16 0.9 [0.6 to 1.7]* −0.2 [−0.5 to 0.4] 0.9 [0.7 to 1.6] 0.042
PDSS score     
  Week 8 12.1 [7.6 to 13.7]* 2.9 [−4.1 to 9.7] 10.7 [6.9 to 16.5] 0.026
  Week 12 11.9 [7.1 to 14.2]* 3.3 [−6.6 to 7.3] 9.8 [8.7 to 15.9] 0.029
  Week 16 9.8 [7.0 to 14.6]* 3.2 [−4.9 to 5.1] 9.9 [7.4 to 17.6] 0.048
UPDRS score     
  Week 8 −6.6 [−11.4 to −2.8] −1.7 [−2.8 to 3.9] −4.9 [−6.7 to −2.7] 0.076
  Week 12 −5.7 [−10.8 to −1.9] −0.9 [−1.7 to 2.1] −5.1 [−8.3 to −2.4] 0.069
  Week 16 −5.2 [−8.9 to −2.1] 2.1 [−4.2 to 6.1] −4.6 [−7.5 to −3.1] 0.153
  1. *: P < 0.05, compared with baseline.